SCNX files prospectus supplement for up to $150M common stock sales

Rhea-AI Filing Summary

Scienture Holdings, Inc. (SCNX) filed a prospectus supplement to its Form S-3, increasing the amount of common stock it is eligible to sell under its equity distribution agreement with Maxim Group LLC to an aggregate offering price of up to $150 million.

According to the filing, $150 million remains available to be sold pursuant to the prospectus supplement. The agreement with Maxim is dated September 19, 2025, and the supplement was filed on November 7, 2025. The notice also states it is not an offer or solicitation where such actions would be unlawful.

Insights

Capital markets analyst

SCNX set up capacity for up to $150M in ATM sales.

Scienture Holdings disclosed a prospectus supplement enabling issuance of common stock under an existing equity distribution agreement with Maxim Group LLC, up to an aggregate $150,000,000. As of the notice, the entire $150,000,000 remains available.

This structure typically permits flexible sales, but activity depends on market conditions and company decisions. The excerpt does not detail timing, pricing, or proceeds allocation beyond the aggregate limit.

Subsequent disclosures may outline execution details, including any shares sold under this capacity and related financial effects.

false 0001382574 0001382574 2025-11-07 2025-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2025

SCIENTURE HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-39199		46-3673928
(State or other jurisdiction of incorporation)		(Commission File No.)		(I.R.S. Employer Identification No.)

20 Austin Blvd.

Commack, NY 11725

(Address of Principal Executive Offices)

(631) 670-6039

(Registrant’s Telephone Number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.00001 per share		SCNX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On November 7, 2025, Scienture Holdings, Inc. (the “Company”) filed with the Securities and Exchange Commission a prospectus supplement to its Registration Statement on Form S-3 (Registration No. 333-289198) increasing the amount of shares of the Company’s common stock, par value $0.00001 per share, that the Company is eligible to sell pursuant to the equity distribution agreement with Maxim Group LLC, dated September 19, 2025, to an aggregate offering price of up to $150 million. As of the date hereof, $150 million remains available to be sold pursuant to the prospectus supplement. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Company’s common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
5.1		Opinion of Dykema Gossett PLLC
23.1		Consent of Dykema Gossett PLLC (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCIENTURE HOLDINGS, INC.
	By:	/s/ Dr. Narasimhan Mani
		Dr. Narasimhan Mani
		Co-Chief Executive Officer
Date: November 13, 2025

FAQ

What did Scienture Holdings (SCNX) announce?

It filed a prospectus supplement increasing eligibility to sell common stock under its Maxim Group LLC agreement to an aggregate offering price of up to $150 million.

How much capacity remains available for SCNX under the program?

As stated, $150 million remains available to be sold pursuant to the prospectus supplement.

Who is the sales agent for Scienture’s equity distribution?

The equity distribution agreement is with Maxim Group LLC, dated September 19, 2025.

When was the prospectus supplement filed by SCNX?

The supplement was filed on November 7, 2025.

What securities are covered under SCNX’s supplement?

The supplement covers sales of common stock, par value $0.00001 per share, up to an aggregate $150 million.

Does this announcement constitute an offer to sell SCNX shares?

No. The notice specifies it does not constitute an offer or solicitation where such actions would be unlawful.